title: Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States.
abstract: During April 2009-June 2010, thirty-seven (0.5%) of 6,740 pandemic (H1N1) 2009 viruses submitted to a US surveillance system were oseltamivir resistant. Most patients with oseltamivir-resistant infections were severely immunocompromised (76%) and had received oseltamivir before specimen collection (89%). No evidence was found for community circulation of resistant viruses; only 4 (unlinked) patients had no oseltamivir exposure.
authors.affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
authors.forename: Samuel B
authors.initials: SB
authors.lastname: Graitcer
authors.forename: Larisa
authors.initials: L
authors.lastname: Gubareva
authors.forename: Laurie
authors.initials: L
authors.lastname: Kamimoto
authors.forename: Saumil
authors.initials: S
authors.lastname: Doshi
authors.forename: Meredith
authors.initials: M
authors.lastname: Vandermeer
authors.forename: Janice
authors.initials: J
authors.lastname: Louie
authors.forename: Christine
authors.initials: C
authors.lastname: Waters
authors.forename: Zack
authors.initials: Z
authors.lastname: Moore
authors.forename: Katrina
authors.initials: K
authors.lastname: Sleeman
authors.forename: Margaret
authors.initials: M
authors.lastname: Okomo-Adhiambo
authors.forename: Steven A
authors.initials: SA
authors.lastname: Marshall
authors.forename: Kirsten
authors.initials: K
authors.lastname: St George
authors.forename: Chao Yang
authors.initials: CY
authors.lastname: Pan
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: LaPlante
authors.forename: Alexander
authors.initials: A
authors.lastname: Klimov
authors.forename: Alicia M
authors.initials: AM
authors.lastname: Fry
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002648:Child; D002675:Child, Preschool; D024882:Drug Resistance, Viral; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects* / Q000472:pathogenicity; D007251:Influenza, Human / Q000453:epidemiology / Q000401:mortality / Q000503:physiopathology / Q000821:virology; D008297:Male; D008875:Middle Aged; D009439:Neuraminidase / Q000037:antagonists & inhibitors; D053139:Oseltamivir / Q000008:administration & dosage / Q000494:pharmacology*; D058873:Pandemics; D011159:Population Surveillance / Q000379:methods; D014481:United States / Q000453:epidemiology; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D053139:Oseltamivir; D009439:Neuraminidase